Market Chatter: AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate

MT Newswires Live03-10 02:47

AtaiBeckley (ATAI) is exploring a potential sale or partnership for BPL-003, a psychedelic drug candidate for severe depression, seeking to fetch at least $2 billion from a deal, Bloomberg reported Saturday, citing people familiar with the matter.

The company could sign a co-commercialization deal, under which AtaiBeckley would share obligations, including stage 3 trial expenses and marketing for BPL-003, while splitting revenues and profits with a partner, Bloomberg said, citing the people.

AtaiBeckley could also work out a royalty deal, the people reportedly said, adding that the company aims to conclude talks in Q2.

Talks are ongoing, and no final decisions have been made, the people added, according to the report.

AtaiBeckley did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 3.73, Change: +0.34, Percent Change: +9.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618167931?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 02:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618167931","market":"nz","top_or_hot":-1,"title":"Market Chatter: AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> AtaiBeckley (ATAI) is exploring a potential sale or partnership for BPL-003, a psychedelic drug candidate for severe depression, seeking to fetch at least $2 billion from a deal, Bloomberg reported Saturday, citing people familiar with the matter.</p><p>The company could sign a co-commercialization deal, under which AtaiBeckley would share obligations, including stage 3 trial expenses and marketing for BPL-003, while splitting revenues and profits with a partner, Bloomberg said, citing the people.</p><p>AtaiBeckley could also work out a royalty deal, the people reportedly said, adding that the company aims to conclude talks in Q2.</p><p>Talks are ongoing, and no final decisions have been made, the people added, according to the report.</p><p>AtaiBeckley did not immediately respond to MT Newswires' request for comment.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 3.73, Change: +0.34, Percent Change: +9.88</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-10 02:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AtaiBeckley (ATAI) is exploring a potential sale or partnership for BPL-003, a psychedelic drug candidate for severe depression, seeking to fetch at least $2 billion from a deal, Bloomberg reported Saturday, citing people familiar with the matter.</p><p>The company could sign a co-commercialization deal, under which AtaiBeckley would share obligations, including stage 3 trial expenses and marketing for BPL-003, while splitting revenues and profits with a partner, Bloomberg said, citing the people.</p><p>AtaiBeckley could also work out a royalty deal, the people reportedly said, adding that the company aims to conclude talks in Q2.</p><p>Talks are ongoing, and no final decisions have been made, the people added, according to the report.</p><p>AtaiBeckley did not immediately respond to MT Newswires' request for comment.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 3.73, Change: +0.34, Percent Change: +9.88</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618167931","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618167931","pubTimestamp":1773082048,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AtaiBeckley  is exploring a potential sale or partnership for BPL-003, a psychedelic drug candidate for severe depression, seeking to fetch at least $2 billion from a deal, Bloomberg reported Saturday, citing people familiar with the matter.The company could sign a co-commercialization deal, under which AtaiBeckley would share obligations, including stage 3 trial expenses and marketing for BPL-003, while splitting revenues and profits with a partner, Bloomberg said, citing the people.AtaiBeckley could also work out a royalty deal, the people reportedly said, adding that the company aims to conclude talks in Q2.Talks are ongoing, and no final decisions have been made, the people added, according to the report.AtaiBeckley did not immediately respond to MT Newswires' request for comment.Price: 3.73, Change: +0.34, Percent Change: +9.88","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ATAI":"Atai Beckley Inc","BK4007":"制药"},"translate_title":"市场热议：AtaiBeckley探索迷幻药候选药物的潜在销售和合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATAI":1},"content_text":"AtaiBeckley (ATAI) is exploring a potential sale or partnership for BPL-003, a psychedelic drug candidate for severe depression, seeking to fetch at least $2 billion from a deal, Bloomberg reported Saturday, citing people familiar with the matter.The company could sign a co-commercialization deal, under which AtaiBeckley would share obligations, including stage 3 trial expenses and marketing for BPL-003, while splitting revenues and profits with a partner, Bloomberg said, citing the people.AtaiBeckley could also work out a royalty deal, the people reportedly said, adding that the company aims to conclude talks in Q2.Talks are ongoing, and no final decisions have been made, the people added, according to the report.AtaiBeckley did not immediately respond to MT Newswires' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: 3.73, Change: +0.34, Percent Change: +9.88","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618167931","isCrawlerRequest":true}